Completed
PHASE2
INTERVENTIONAL
NCT00425256
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Interventions
Name:
Bremelanotide
Type:
DRUG
Description:
Trial Information
NCT ID
NCT00425256
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Palatin Technologies, Inc
Last Updated
December 15, 2025